Industries

Pharma & API

Drug makers and generic suppliers, read through their filings, FDA drug shortages, recalls and approvals, tariff and FDA rules, and where US drug and ingredient imports come from.

Companies covered
12
Latest quarter filed
Sep 30, 2026
SEC filings, last 30 days
30
Comment periods open
2
SEC EDGAR read
20:36 UTC, Nov 20

The numbers

US government series, latest print and the change on a year earlier · Federal Reserve Bank of St. Louis (FRED)

US output, pharmaceuticals

122.5

index, 2017 = 100

+0.5% on a year earlier

Oct 2026 · FRED IPG3254S

Producer prices, pharmaceuticals

590.2

index

+1.0% on a year earlier

Oct 2026 · FRED PCU32543254

Ninety days of filings

Every SEC filing by the companies below, one row each · move across to read a day

Fri, Nov 20, 2026

No filings by the covered companies

Aug 23 to Nov 20 · 45 filings, 3 in the last seven days · SEC EDGAR. Tall: quarterly and annual reports. Middle: current reports (8-K). Short: other forms. Red: an 8-K item that says something went wrong.

What changed

Filings by the companies below, last 30 days · SEC EDGAR

16 more in the period, on each company’s EDGAR page.

Rules and notices

Federal Register, last 45 days

Matched by title against the industry’s terms; paperwork renewals and meeting notices left out · read 21:04 UTC, Nov 20

Who is exposed

Trailing twelve months to each company’s latest quarter, from its own XBRL filings · SEC EDGAR
Across Revenue growth, last twelve months on the twelve beforeUp Operating margin, last twelve monthsSize Revenue, last twelve monthsRing Filed a current report (8-K) this week; red if it says something went wrongDot inside Beyond the scale, pinned to its edge

CompanyQuarter toRevenueGrowthGross marginOp. marginCapex / revenueCapex growthInventory daysBacklog
Eli Lilly LLYBranded drugsSep 30, 2026$86.5B+45.5%83.6%———469—
Johnson & Johnson JNJBranded drugs and devicesSep 27, 2026$99.3B+7.8%67.6%—5.6%+20.9%174—
Merck MRKBranded drugs and vaccinesSep 30, 2026$67.4B+4.9%71.8%—5.9%-1.5%118—
Pfizer PFEBranded drugs and vaccinesSep 27, 2026$63.6B+1.3%73.4%—3.8%-11.6%216—
AbbVie ABBVBranded drugsSep 30, 2026$66.0B+10.7%73.7%32.2%1.8%+3.5%112—
Bristol Myers Squibb BMYBranded drugsSep 30, 2026$50.0B+4.2%69.2%—2.7%+3.6%64—
Amgen AMGNBiologicsSep 30, 2026$38.9B+8.2%70.9%32.4%6.3%+54.6%206—
Gilead GILDAntiviralsSep 30, 2026$31.0B+6.5%79.9%-7.6%2.3%+38.4%111—
Regeneron REGNBiologicsSep 30, 2026$16.9B+18.6%—28.8%6.0%+20.1%——
Vertex VRTXSpecialty drugsSep 30, 2026$13.0B+10.5%85.5%33.2%3.8%+29.3%437—
Viatris VTRSGenericsSep 30, 2026$14.7B+4.3%35.3%-0.0%2.5%+16.2%147—
Teva TEVAGenericsSep 30, 2026$17.2B+2.7%53.5%8.3%3.1%+9.4%145—
Median of 12 with a current year+7.2%71.8%28.8%3.8%

Growth compares the latest twelve months with the twelve before. A quarter a company reports only inside a year-to-date total is the difference of the two totals it filed; a ratio is shown only when both sides cover the same four quarters. Backlog is remaining performance obligations, with its change on a year earlier. A dash means the company does not report that line.

Drug shortages

FDA drug shortage list · openFDA
Products in shortage now
1,116
To be discontinued
403
  • Nov 19Eugia US LLC · AnesthesiaLidocaine Hydrochloride Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · RheumatologyMethylprednisolone Acetate Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · AnesthesiaRopivacaine Hydrochloride Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · AnesthesiaEtomidate Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · CardiovascularFurosemide Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · OncologyAzacitidine Injection: unavailable, demand increase for the drug
  • Nov 19Eugia US LLC · DermatologyDexamethasone Sodium Phosphate Injection: unavailable, demand increase for the drug
  • Nov 18Fresenius Kabi USA, LLC · Analgesia/AddictionKetorolac Tromethamine Injection: unavailable

Newest updates to products listed as unavailable; counts are package listings, not distinct drugs · read 20:37 UTC, Nov 20

Drug recalls

FDA enforcement reports, last 60 days · openFDA
  • Nov 11Class II · Victory Medical Center PharmacyTHYMOSIN ALPHA-1 (MDV) 3MG/ML **5ML**: Lack of Processing Controls
  • Nov 11Class II · Victory Medical Center PharmacyCAGRILINTIDE/GLYCINE/B12 (MDV) 3.75/5/1MG/ML **1ML**: Lack of Processing Controls
  • Nov 11Class II · Victory Medical Center PharmacyCJC-1295/IPAMORELIN (MDV) 2/2MG/ML **5ML**: Lack of Processing Controls
  • Nov 11Class II · Victory Medical Center PharmacyTIRZEPATIDE/L-CARNITINE **10/50MG/ML** (MDV) **1ML**: Lack of Processing Controls
  • Nov 11Class II · Preferred Pharmaceuticals, Inc.Artificial Tears Lubricant Eye Drops: Lack of Assurance of Sterility
  • Nov 11Class II · American Health PackagingCyanocobalamin Injection: Presence of particulate matter:American Regent, Inc. notified BluePoint Pharmaceuticals Laboratories regarding potential glass particle cont
  • Nov 11Class II · Victory Medical Center PharmacyCJC-1295/IPAMORELIN (MDV) 2/2MG/ML **2ML**: Lack of Processing Controls
  • Nov 11Class II · Fresenius Medical Care Renal Therapies Group, LLCDELFLEX Peritoneal Dialysis Solution with 4.25% Dextrose: Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the pri

Class I is the FDA’s most serious recall class · read 20:37 UTC, Nov 20

What to watch

Comment deadlines and effective dates ahead · Federal Register

Where US supply comes from

US imports, Aug 2026 · UN Comtrade
  • HS 3004Medicines in doses · $7.2B · +29.3% on a year earlierSwitzerland 15% · India 11% · Ireland 11%
  • HS 3002Vaccines, blood and biologics · $5.8B · -15.6% on a year earlierSouth Korea 15% · Ireland 14% · Italy 12%
  • HS 2941Antibiotics · $43M · -47.9% on a year earlierChina 43% · Italy 16% · Denmark 10%
  • HS 2933Drug ingredients (heterocyclic compounds) · $502M · -40.9% on a year earlierChina 25% · United Kingdom 12% · India 12%

Every industry’s suppliers, country by country →

ARCANE reporting

Published investigations that land on this page

No published ARCANE article on pharma & api yet. The article runner commissions one for this page; it appears here once accepted.

Ask Alpha about pharma & api →